CRESY
CRESUD INC
$10.92
-3.53%
$774.5M
No data for this timeframe.
Vol
Market Cap$774.5M
Cap SizeSmall Cap
Inst. Holders4 funds
Inst. Value$2.7M
Inst. Activity1 buys / 2 sells
Insider Activity6B / 0S
Insider Net $$1.2M
Reddit Sentiment67° Warm
SEC Reports7
Recent Activity
Jun 5, 2026
Insider
Elsztain Alejandro Gustavo bought 18,200 shares
Director @ $10.95 ($199.3K)
May 26, 2026
SEC
Cresud reported mixed Q3 FY2026 results with total revenue +15% YoY to ARS 965.5B and net income attributable to parent
6-K — Impact 5/10
May 21, 2026
SEC
Two directors at Cresud (CRESY) made open-market purchases totaling $275K over the past week, with Eduardo Elsztain buyi
CLUSTER — Impact 5/10
May 20, 2026
Insider
Zang Saul bought 17,000 shares
Director @ $10.63 ($180.8K)
May 14, 2026
Insider
ELSZTAIN EDUARDO S bought 8,823 shares
Director @ $10.67 ($94.1K)
May 8, 2026
SEC
Cresud Inc. filed a 6-K reporting the routine third installment interest payment on its Series XLVII Fixed Rate Notes (U
6-K — Impact 2/10
Inst.
MORGAN STANLEY — DOUBLED
183,853 shares ($2.3M)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
28,834 shares ($364.2K)
Price Targets
Historical data — last covering-analyst action Apr 2014. No current recommendation available.
$15.51 (Apr 2014)
Current $10.92
Low $15.01
Median $15.51
High $16.00
2 analysts
$15.01
$16.00
Analyst Ratings
4Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 7, 2014 | Morgan Stanley | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $0.11 ▼ -58.4% | $0.11 — $0.11 | 1 | |
| Next FY | $0.07 ▼ -36.2% | $0.07 — $0.07 | -37% YoY | 1 |
Latest Reports
MIXED
6-K
5/10
Cresud reported mixed Q3 FY2026 results with total revenue +15% YoY to ARS 965.5B and net income attributable to parent
May 26, 2026
BULLISH
CLUSTER
5/10
Two directors at Cresud (CRESY) made open-market purchases totaling $275K over the past week, with Eduardo Elsztain buyi
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $2.3M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $364.2K | TRIM |
| BANK OF AMERICA CORP | $38.1K | TRIM |
| WELLS FARGO & COMPANY/MN | $1.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Elsztain Alejandro | BUY | $199.3K |
| May 20, 2026 | Zang Saul | BUY | $180.8K |
| May 14, 2026 | ELSZTAIN EDUARDO | BUY | $94.1K |
| May 13, 2026 | ELSZTAIN EDUARDO | BUY | $619.3K |
| Apr 23, 2026 | Elsztain Alejandro | BUY | $49.9K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
4 institutional holders with $2.7M total value (215,705 shares) as of 2025-Q4. Top holders: MORGAN, TWO, BANK. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 183,853 | $2.3M | 85.2% | DOUBLED +132.1% |
| 2 | TWO SIGMA INVESTMENTS, LP | 28,834 | $364.2K | 13.4% | TRIM -30.4% |
| 3 | BANK OF AMERICA CORP /DE/ | 3,018 | $38.1K | 1.4% | TRIM -44.0% |
| 4 | WELLS FARGO & COMPANY/MN | — | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 79,209 | 183,853 | +132.1% | $2.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 41,402 | 28,834 | -30.4% | $364.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 5,388 | 3,018 | -44.0% | $38.1K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 148,330 | 79,209 | -46.6% | $728.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 8,192 | 5,388 | -34.2% | $49.6K | 2025-Q3 |
| UBS Group AG | TRIM | 457,155 | 251,217 | -45.0% | $2.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 50,210 | — | $540.3K | 2025-Q2 |
| UBS Group AG | ADD | 306,441 | 457,155 | +49.2% | $5.1M | 2025-Q1 |
| UBS Group AG | DOUBLED | 138 | 306,441 | +221958.7% | $3.9M | 2024-Q4 |
| MORGAN STANLEY | ADD | 104,405 | 141,934 | +35.9% | $1.8M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 31,749 | 91,036 | +186.7% | $1.1M | 2024-Q4 |
3 unique insiders with 6 transactions. Net insider value: $1.2M ($1.2M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Elsztain Alejandro Gustavo | Director | BUY | 18,200 | $10.95 | $199.3K |
| May 20, 2026 | Zang Saul | Director | BUY | 17,000 | $10.63 | $180.8K |
| May 14, 2026 | ELSZTAIN EDUARDO S | Director | BUY | 8,823 | $10.67 | $94.1K |
| May 13, 2026 | ELSZTAIN EDUARDO S | Director | BUY | 58,595 | $10.57 | $619.3K |
| Apr 23, 2026 | Elsztain Alejandro Gustavo | Director | BUY | 4,458 | $11.20 | $49.9K |
| Apr 22, 2026 | Elsztain Alejandro Gustavo | Director | BUY | 8,917 | $11.25 | $100.3K |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 3.7/10.
MIXED
6-K
5/10
Cresud reported mixed Q3 FY2026 results with total revenue +15% YoY to ARS 965.5B and net income att
May 26, 2026
BULLISH
CLUSTER
5/10
Two directors at Cresud (CRESY) made open-market purchases totaling $275K over the past week, with E
May 21, 2026
NEUTRAL
6-K
2/10
Cresud Inc. filed a 6-K reporting the routine third installment interest payment on its Series XLVII
May 8, 2026
BULLISH
6-K
6/10
Cresud reported nine-month results for fiscal 2026 with net income surging to ARS 231,308 million (v
May 7, 2026
NEUTRAL
6-K
3/10
Cresud issued USD 64.2 million in two tranches of local-market notes (Series LII: USD 41.2M at 4.75%
Apr 28, 2026
NEUTRAL
6-K
3/10
CRESUD INC is making the third installment payment of capital on its Series XLII Fixed Rate Notes, t
Apr 24, 2026
NEUTRAL
6-K
2/10
CRESUD INC announced the payment of the fourth interest installment on its Series XLV Fixed Rate Not
Apr 15, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2014): 89% buy across 9 analysts — 4 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Apr 2014. No current recommendation available.
$15.51 mean target (Apr 2014)
$15.01 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $10.92 |
| Target Low | $15.01 |
| Target Mean | $15.51 |
| Target Median | $15.51 |
| Target High | $16.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$0.11 | $0.11 | $0.11 | — | -58.4% | 0↑ 1↓ | $1192.5B | 30.4% | 1 |
| Next FY 2027-06-30 |
$0.07 | $0.07 | $0.07 | -37.4% | -36.2% | 0↑ 1↓ | $1390.4B | 16.6% | 1 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 7, 2014 | Morgan Stanley | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Aug 1, 2025 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Jul 1, 2025 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Jun 1, 2025 | 4 | 4 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.